DIAGNOSTIC PERFORMANCE OF POOLED RT-PCR TESTING FOR SARS-COV-2 DETECTION

Authors: Diadem Ricarte^{1,2}, Aubrey Gador^{1,2}, Leomill Mendiola^{1,2}, Ian Christian Gonzales^{2,3}

¹Northern Mindanao Medical Center COVID-19 Satellite Laboratory

²Infectious Disease Cluster, Department of Health Center for Health Development Northern Mindanao

³Department of Health Philippines – Center for Health Development Northern Mindanao

ABSTRACT

Background: With the high number of COVID-19 cases, a need to optimize testing strategy must be regarded to obtain timely diagnosis for early containment measures. With this, several studies have employed pooled RT-PCR testing for SARS-CoV-2 as this could potentially conserve laboratory resources while has the capacity to test several individuals. However, this was recommended to firstly validate the method as different laboratory reagents and equipment vary with its diagnostic performance.

Objective: The aim of this study was to determine the diagnostic performance of pooled SARS-CoV-2 nasopharyngeal/oropharyngeal swabbed samples using RT-PCR technique.

Methods: A records review of two-staged pooled RT-PCR testing data from August 10, 26, 30 and September 5, 2020 was utilized from Northern Mindanao Medical Center COVID-19 Satellite Laboratory (formerly CHDNM TB Regional Center). For the first stage, using known samples, a total of 30 pools were made for each of the pooling size, 5- and 10-pooled, on both pooling phase, pre- and post-RNA extraction. One positive individual was used to represent each of the Cycle threshold values given (<24, 25-28, 29-32, 33-36, and 37-40) while the rest of the samples were negative. For the second stage, 54 pools of five from 270 random unknown samples were used to validate the results. Target gene performance of N gene and RdRp was also determined.

Key Results: Results show that 5-pooled sample has higher sensitivity (SN), specificity (SP), positive predictive value (PPV), and negative predictive value (NPV) of 100% (95% confidence interval (CI) 88.97-100), 66.95% (95% CI, 60.75-72.6), 28.18% (95% CI, 20.62-37.22), and 100% (95% CI, 97.66-100) compared to 10-pooled sample that has 87.1% (95% CI, 71.15-94.87), 56.9% (50.57-63.02), 20.77% (95% CI, 14.68-28.53) and 97.14% (95% CI, 92.88-98.88). Further, these Ct values were only from the N gene, emphasizing its higher diagnostic performance as well to detect SARS-CoV-2 compared to RdRp as only a few samples were detected, thus, no analysis was made.

Conclusion: This study found out that 5-pooled sample has better diagnostic performance compared to 10-pooled samples. Specifically, all positive individual samples were detected in 5-pooled samples in pre-RNA extraction phase which these results are evident and consistent on both known and unknown samples. N gene was found out to detect more SARS-CoV-2 samples compared to RdRp.

BACKGROUND

Coronavirus disease 2019, or known as COVID-19, was caused by a novel coronavirus, SARS-CoV-2, originating from the province of Hubei, Wuhan, China (Song, 2020). On January 30, 2020, the World Health Organization (2020) addressed this disease as a public health emergency of international concern as 32,730,945 confirmed COVID-19 cases including 958,703 deaths were tallied as of September 27, 2020. In the case of the Philippines, it has a total of 307,221 cases with 3,077 of these were detected in Northern Mindanao (Department of Health [DOH], 2020).

Detecting SARS-CoV-2 as early as possible displays a fundamental factor in containing its spread. However, with the unprecedented rise of COVID-19 cases, it caused a sudden huge strain on lives and economies as well as on the part of the healthcare system where a demand to upscale testing capacity is needed. While Philippines has now a total of 100 licensed reverse-transcriptase polymerase chain reaction (RT-PCR) laboratories as of August 7, 2020 with an average daily testing capacity of 27,800 in the last seven days (DOH, 2020), it still faces a challenge on the constant supply of laboratory resources as procurement has been difficult due to international competition (Galvez, 2020). In addition, though the use of RT-PCR diagnostic test is highly recommended to detect SARS-CoV-2, the shortage of supplies hampers the need to continually operate and overwhelm finances as well (Levenson, 2020; Owens-Liston, 2020; Scott, 2020). As many are experiencing this crisis, an alternative way of detecting the virus through optimizing strategies to conserve diagnostic kits while still having the capacity to increase testing must be regarded.

The European Center for Disease Control and Prevention (2020) has recommended the use of a pooled testing method where it aids in monitoring the activity of a disease whilst providing a rational use of diagnostic kits especially in low-resource settings (Majid et al., 2020). Also, this strategy can also expand the capacity of the laboratory to conduct surveillance testing (US Centre for Disease Prevention and Control [US CDC], 2020; Rohde, 2020).

Several studies have already employed the use of a pooled testing method to detect SARS-CoV-2 samples (Hogan et al., 2020; Lohse et al., 2020; Bi et al., 2020). However, this has also been recommended to firstly validate as different laboratory reagents and equipment vary with its diagnostic performance (Abdalhamid, 2020), specifically in terms of its sensitivity, specificity, positive predictive value, and negative predictive value. In the context of Northern Mindanao, Philippines, this method was explored in this study, specifically addressed the question, “What is the diagnostic performance of pooled SARS-CoV-2 nasopharyngeal/oropharyngeal swabbed samples using RT-PCR technique?”

With the rising cases of COVID-19 that resulted in shortage of laboratory supplies, this study addresses the need to increase testing capacity in a cost-effective manner as supply problems are globally experienced due to the pandemic. Since this method is not feasible for SARS-CoV-2 standard testing, this approach can be a potential tool to use for epidemiological reasons such as determining the proportion of positive cases within a certain area in the region as local transmission is also occurring. Most especially, Philippines, despite its current capacity, is not testing enough. With this pooled testing method, if proven to be effective, will allow more individuals to be tested and their COVID-19 viral status known, thus, it could potentially improve disease prevention and

control strategies of the government such as aid for early detection of positive cases while assisting policymakers' decisions for their implementation of containment measures. While Northern Mindanao is experiencing a delay in supply logistics that resulted in a backlog of samples, hence, this pooling method can possibly conserve the resources and continue testing individuals.

METHODOLOGY

A retrospective research design was employed to obtain secondary data on SARS-CoV-2 swabbed samples that were collected from nasopharyngeal and oropharyngeal sites of individuals ranging from asymptomatic, mild with no comorbidities, mild with comorbidities, severe and critical cases in Northern Mindanao and that were sent by the trained Medical Technologists to the Northern Mindanao Medical Center COVID-19 Satellite Laboratory (formerly CHDNM TB Regional Center) last August 10, 26, 30, 2020 and September 5, 2020.

Inclusion criteria

- Known and unknown SARS-CoV-2 sample results within the valid control were included for data collection where a positive control had a Ct value of ≤ 22 for RdRp and N gene while a Ct value of ≤ 21 for RNase P (Internal control) and no detection cycles of the genes mentioned for a negative control as also based on the Instruction for Use (IFU) of GeneFinder™ COVID-19 Plus RealAmp Kit. For further validation, the pathologist, two Medical Technologists as well as the Head of the Infectious Disease Cluster verified the control results.
- Individual and pooled samples that were received and tested within 24 hours of receipt to Northern Mindanao Medical Center COVID-19 Satellite Laboratory (formerly CHDNM TB Regional Center) were only included for data collection.

Exclusion criteria

- GeneFinder™ COVID-19 Plus RealAmp Kit uses three target genes: N gene, E gene and RdRp and RNase P as the internal control gene. However, E gene is only interpreted as PRESUMPTIVE POSITIVE if it is detected, thus, this gene was not included for the data collection.

Sampling Method

This study had two stages. First, the pooling data on known (determined) samples was used to identify what ideal sample size and pooling phase could detect the positive samples in each of the Ct value ranges given. Its target genes and diagnostic performance were analyzed. Second, the pooling data on arbitrarily chosen unknown (clinical) samples was then used to validate the ideal results found on the pooled known samples in which its target genes and diagnostic performance were analyzed.

The methodology on how the pooled samples were done prior and after RNA extraction were based on the published literature (Abdalhamid et al., 2020; Gupta et al., 2020; Perchetti et al., 2020; Yelin et al.,

2020) having high diagnostic performance and reliable results, thus, its pooling procedures were synthesized and adopted in this study.

i. Sample preparation

- Combined nasopharyngeal and oropharyngeal swabs were collected by the trained DOH CHDNM Medical Technologists, transported at 2 to 8 degree Celsius in a 2 ml Sanli Virus specimen collection tube; Liuyang, Sanli Medical Technology Devt. Co., China (RITM, 2020), a valid and compatible for the SARS-CoV-2 detection kit used where it states that it is intended for use with RNA extracted from nasopharyngeal swabs, and oropharyngeal swabs. However, there was no ideal transport medium indicated in its Instruction for Use (GeneFinder™ COVID-19 Plus RealAmp Kit, OSANG Healthcare Co., Ltd, South Korea), thus, valid VTM is acceptable. The samples that were sent to the said laboratory were directly processed. While the results of the individual samples were yet to be determined for a turnaround time of 8 to 12 hours, VTM were stored at 4 degree Celsius. Once known, these were then pooled after. Hence, no freeze-thaw cycles were done.
- From the time the samples were received at the laboratory, these were then processed to avoid RNA degradation. Samples were labeled and assigned in a designated pool for each of the Ct value ranges given. After which, these were prepared in pool of 5 and pool of 10 and were pooled in two phases, pre-RNA extraction and post-RNA extraction in three replicates to ensure reproducibility of the results. For a pool of five, one positive and four negative samples were used in each of the Ct value ranges: <24, 25-28, 29-32, 33-36 and 37-40. For a pool of ten, one positive and nine negative samples were used in each of the Ct value ranges: <24, 25-28, 29-32, 33-36 and 37-40. (Supplementary Figure S1 and S2).
- For the first stage, pooling of known samples was used. Samples were pooled right after the results of the individual samples were determined or about 12 hours from the time individual samples were received at the laboratory and tested until these were then pooled. Previously tested samples were stored at 4 degree Celsius prior to pooling. For the second stage, pooling of unknown samples was used. Individual and pooled samples were tested in parallel.

ii. RNA Extraction

An automated extractor, Genolution Nextractor® NX-48S with its nucleic acid reagents, was used for the purification of RNA. The extraction underwent the following steps: lysis of the sample, DNA binding to the magnetic beads, washing and elution.

- Individual samples

A total volume of 200 microliter from each of the universal transport medium buffers was dispensed onto the pre-filled sample well of the automated Genolution Nextractor® NX-48S plate. After loading all the individual samples, these were placed into the auto extractor for RNA purification.

- Pooling of samples prior to RNA extraction

An initial volume of 100 microliter aliquot from each viral transport medium buffer was initially transferred onto a conical tube for the pooling of samples prior to dispensing onto the pre-filled sample well of the automated Genolution Nextractor NX-48S plate. A total volume aliquot of 500 microliter for the 5-pooled sample and 1,000 microliters for the 10-pooled samples. A final volume of 200 microliter, either of the 5- or 10-pooled samples, was dispensed into the pre-filled sample well of the automated Genolution Nextractor NX-48S plate. The samples were pooled in three replicates. Eluted samples were then transferred to a new tube for RT-qPCR test.

- Pooling of samples after RNA extraction

Eluted RNA samples were firstly pooled prior to mixing with the master mix reagent onto the 96-well plate. An aliquot volume of 10 microliter each eluted RNA sample was dispensed initially onto the tube for pooling. A total volume of 50 microliter for the 5-pooled samples and 100 microliters for the 10-pooled samples. A final volume of 5 microliter, either of the 5- or 10-pooled samples, was dispensed onto the 96-well plate for RT-PCR testing.

iii. RT-PCR Testing

After the RNA extraction, RT-PCR test was performed to detect the presence of SARS-CoV-2 RNA using GeneFinder™ COVID-19 Plus RealAmp Kit in Applied Biosystems® 7500 Real-Time PCR Instrument (ABI 7500) machine (Thermo Fisher Scientific Inc.) based on the Instruction for Use (IFU) provided.

A 15 microliter of GeneFinder™ master mix reagent was dispensed onto the 96-well plate. After which, a 5 microliter of eluted samples, either of the individual, 5- or 10-pooled samples, were dispensed. A 96-well plate containing mastermix reagent and eluted RNA sample was placed onto the RT-PCR machine to detect 3 SARS-CoV-2 target genes: N, E, and RdRP.

For quality control, there were three controls provided on the Instruction for Use (IFU) of GeneFinder™ COVID-19 Plus RealAmp Kit. For internal control, RNase P gene with Ct value of ≤ 22 was used while for positive external control, N gene and RdRp with Ct value of ≤ 22 . No detection cycles of the genes mentioned was set for a negative control.

Reactions were heated to 50°C for 20 minutes for reverse transcription, denatured at 95°C for 15 minutes and then 45 cycles were carried for amplification set at 95°C for 15 seconds and 58°C for 1 minute. Fluorescence was measured using four channels: FAM (RdRp gene), JOE (N gene), TEXAS RED (E gene), and CY5 (RNase P). After which, the data on the individual and pooled SARS-CoV-2 NP/OP swabbed samples were validated and will be obtained for analysis.

RESULTS AND DISCUSSION

Study Samples

Pooling of previously known samples

A total of 450 known samples were utilized for this stage. A positive sample was used to represent each of the cycle threshold values given. There were 150 known samples used for pooling of five while 300 samples were used for pooling of 10 that consist of one positive sample and four negative samples in each of the five Ct value ranges and were pooled in two phases, prior to RNA extraction or after RNA extraction, in three replicates.

i. Pooling of 5-pooled samples

Table 1 shows that all five positive individual samples were detected when pooled in pre-RNA extraction phase only. On the other hand, a positive sample with an N gene Ct value of 37.66 (Ct value range 37-40) was negative when pooled in post-RNA extraction phase (Ct Mean: 41.85; SD: 7.94). Meanwhile, no analysis for RdRp Ct values was made as it was undetected for most of the samples (Table 2).

Table 1. Cycle threshold values of N gene in previously known individual and 5-pooled samples in the given RNA extraction phase.

Ct value range	Individual Samples ^a	Pooled Samples	
		Pre RNA extraction	Post RNA extraction
		Mean (SD)*	Mean (SD)*
<24	17.6	19.14 (0.87)	21.51 (0.71)
25-28	25	26.08 (0.62)	28.00 (0.06)
29-32	31.26	31.01 (0.53)	34.12 (2.52)
33-36	33.23	32.29 (0.03)	33.98 (1.80)
37-40	37.66	34.82 (2.15)	41.85 (7.94) ^b

^aIndividual samples refer to the Ct values of known positive samples only

^bSARS-CoV-2 is not detected

SD: Standard deviation

*done in triplicates

Table 2. Frequency of RdRp gene in 5-pooled samples in the given RNA extraction phase.

Pre RNA-Extraction		Post-RNA Extraction	
Detected	Undetected	Detected	Undetected
3	12	2	13

ii. Pooling of 10-pooled samples

Results show that one positive individual sample with a Ct value of 37.66 (Ct value range: 37-40) cannot be detected when pooled on both RNA extraction phases (Table 3). Meanwhile, no analysis for RdRp Ct values was made as it was undetected for most of the samples (Table 4).

Table 3. Cycle threshold values of N gene in previously known individual and 10-pooled samples in the given RNA extraction phase.

Ct value range	Individual Samples ^a	Pooled Samples	
		Pre RNA extraction	Post RNA extraction
		Mean (SD)*	Mean (SD)*
<24	17.6	20.48 (0.36)	22.24 (0.06)
25-28	25	27.16 (1.15)	29.40 (0.16)
29-32	31.26	32.76 (1.80)	33.38 (0.88)
33-36	33.23	35.02 (1.21)	34.62 (0.45)
37-40	37.66	-	-

^aIndividual samples refer to the Ct values of known positive samples only

SD: Standard deviation

*done in triplicates

Table 4. Frequency of RdRp gene in 10-pooled samples in the given RNA extraction phase.

Pre RNA-Extraction		Post-RNA Extraction	
Detected	Undetected	Detected	Undetected
1	14	1	14

Validation of pool testing using random unknown samples

As all known individual positive samples can only be detected when these are pooled in five in pre-RNA extraction phase, the results were validated with 270 unknown samples. These were sorted in 54 pools. Results show that all 31 samples that tested positive on individual testing, which got sorted into 22 pools, were also detected in pooled sample testing. These positive pools were composed of one positive sample (14/22), two positive samples (7/22), and three positive samples (1/22) (Supplementary Table S1).

Main Results of the Study

Difference between pooling sizes in two pooling phases of the given Cycle threshold value ranges.

To compare the difference between 5-pooled and 10-pooled known nasopharyngeal/oropharyngeal swabbed samples that is pooled in each RNA extraction phase in detecting SARS-CoV-2 in Ct value ranges of <24, 25-28, 29-32, 33-36, 37-40, Open Epi was used to analyze the set of data.

Table 5 shows that there is no significant difference between 5- and 10-pooled samples in Ct value range of 29-32 (95 CI: -0.68, 2.16) and 33-36 (95 CI: -1.65, 0.37) in post-RNA extraction phase. Further, a known positive sample in Ct value range of 37-40 is negative in 5-pooled sample of post-RNA extraction phase and is undetected in 10-pooled samples for both RNA extraction phases.

Table 5: N gene mean Ct values of pooled samples in pre- and post-extraction phase.

Ct value range	Pre-RNA Extraction			Post-RNA Extraction		
	5-pooled	10-pooled	95 CI of difference	5-pooled	10-pooled	95 CI of difference
<24	19.14	20.48	(-1.84, -0.84)	21.51	22.24	(-1.12, -0.34)
25-28	26.08	27.16	(-1.61, -0.55)	28	29.4	(-1.47, -1.33)
29-32	31.01	32.76	(-2.47, -1.03)	34.12	33.38	(-0.68, 2.16)
33-36	32.29	35.02	(-3.18, -2.28)	33.98	34.62	(-1.65, 0.37)
37-40	34.82	-	-	41.85	-	-

Performance of the target genes in two pooling sizes in pre-RNA extraction phase

To compare the diagnostic performance between the target genes, N gene and RdRp, in detecting unknown 5-pooled and 10-pooled SARS-CoV-2 nasopharyngeal/oropharyngeal swabbed samples that is pooled in pre-RNA extraction phase, Microsoft Excel and Open Epi was used to analyze the set of data.

Using 2x2 table analysis (Table 6, 7, 9, and 10), results show that N gene of 5-pooled sample has higher diagnostic performance in terms of its sensitivity, positive predictive value, and negative predictive value. On the other hand, RdRp of 5-pooled sample is more specific. However, there is no significant difference between the target genes, N gene and RdRp, for both pooling sizes, 5-pooled and 10-pooled samples, in detecting SARS-CoV-2 nasopharyngeal/oropharyngeal swabbed samples (Table 8 and 11).

Table 6. 2x2 table analysis of individual samples and 5-pooled N gene.

		Individual samples		
5-pooled N gene		(+)	(-)	Total
	(+)	30	80	110
	(-)	1	159	160
		31	239	270

Table 7. 2x2 table analysis of individual samples and 5-pooled RdRp.

		Individual samples		
5-pooled RdRp		(+)	(-)	Total
	(+)	24	66	90
	(-)	7	173	180
		31	239	270

Table 8. Diagnostic performance of target genes of 5-pooled samples.

5-POOLED SAMPLES				
	N gene	95% CI	RdRp	95% CI
Sensitivity	96.77%	(83.81, 99.43)	77.42%	(60.19, 88.61)
Specificity	66.53%	(60.32, 72.21)	72.38%	(66.4, 77.67)
Positive Predictive Value	27.27%	(19.82, 36.26)	26.67%	(18.62, 36.62)
Negative Predictive Value	99.38%	(96.55, 99.89)	96.11%	(92.19, 98.1)

Table 9. 2x2 table analysis of individual samples and 10-pooled N gene.

		Individual samples		
10-pooled N gene		(+)	(-)	Total
	(+)	25	75	100
	(-)	6	164	170
		31	239	270

Table 10. 2x2 table analysis of individual samples and 10-pooled RdRp.

		Individual samples		
10-pooled RdRp		(+)	(-)	Total
	(+)	27	103	130
	(-)	4	136	140
		31	239	270

Table 11. Diagnostic performance of target genes of 10-pooled samples.

10-POOLED SAMPLES				
	N gene	95% CI	RdRp	95% CI
Sensitivity	87.1%	(71.15, 94.87)	80.65%	(63.72, 90.81)
Specificity	56.9%	(50.57, 63.02)	68.62%	(62.48, 74.17)
Positive Predictive Value	20.77%	(14.68, 28.53)	25.00%	(17.55, 34.3)
Negative Predictive Value	97.14%	(92.88, 98.88)	96.47%	(92.51, 98.37)

Performance of the two pooling sizes in pre-RNA extraction phase

To compare the diagnostic performance of the pooling method of unknown 5-pooled and 10-pooled SARS-CoV-2 nasopharyngeal/oropharyngeal swabbed samples that is pooled in pre-RNA extraction phase, Microsoft Excel and Open Epi was used to analyze the set of data.

Using 2x2 table analysis (Table 12 and 13), Table 14 shows that 5-pooled samples have higher diagnostic performance compared to 10-pooled samples. However, there is no significant difference between the two pooling sizes.

Table 12. 2x2 table analysis of individual and 5-pooled samples.

Individual samples				
10-pooled		(+)	(-)	Total
	(+)	31	79	110
	(-)	0	160	160
		31	239	270

Table 13. 2x2 table analysis of individual and 10-pooled samples.

Individual samples				
10-pooled		(+)	(-)	Total
	(+)	27	103	130
	(-)	4	136	140
		31	239	270

Table 14. Diagnostic performance of 5- and 10-pooled samples.

POOLED SAMPLES				
	5-pooled	95% CI	10-pooled	95% CI
Sensitivity	100%	(88.97, 100)	87.1%	(71.15, 94.87)
Specificity	66.95%	(60.75, 72.6)	56.9%	(50.57, 63.02)
Positive Predictive Value	28.18%	(20.62, 37.22)	20.77%	(14.68, 28.53)
Negative Predictive Value	100%	(97.66, 100)	97.14%	(92.88, 98.88)

Discussion

This study found out that 5-pooled sample in pre-RNA extraction phase has higher diagnostic performance as results are evident and consistent on both known and unknown samples. To further elaborate, it has a sensitivity (SN), specificity (SP), positive predictive value (PPV), and negative predictive value (NPV) of 100% (95% confidence interval (CI) 88.97-100), 66.95% (95% CI, 60.75-72.6), 28.18% (95% CI, 20.62-37.22), and 100% (95% CI, 97.66-100) compared to 10-pooled sample that has 87.1% (95% CI, 71.15-94.87), 56.9% (50.57-63.02), 20.77% (95% CI, 14.68-28.53) and 97.14% (95% CI, 92.88-98.88), respectively (Table 8 and 11). However, the diagnostic performance of SARS-CoV-2 pooling method by Abdalhamid et. al. (2020) which has SN of 95% and SP of 100% using five samples and de Salazar et. al. (2020) which has SN, SP, PPV and NPV of 97.10% (95% CI, 94.11-98.82), 100%, 100% and 99.79% (95% CI, 99.56-99.90) on pooling of ten samples were higher than the results of this study. This may probably be due to higher sensitivity of the viral detection kit used as it potentially contribute on the diagnostic performance of the pooling method.

In this study, the higher diagnostic performance of 5-pooled sample is expected as these were diluted less than 10-pooled which tends to increase the cycle threshold value and lowers the viral load. This is also apparent when pooling was firstly done on known samples as only 5-pooled in pre-RNA extraction phase could be able to detect all known individual positive samples, specifically the N gene, on all the cycle threshold value ranges given (Table 1 & 5). According to Abdalhamid et. al. (2020), pooling of five samples is also efficient as it could yield a 69% increase in testing capability, highlighting the importance of the method to address the shortage of supplies. These findings are also similar with the study of Chhikara et. al. (2020) and Alcoba-Florez et. al. (2020) where they concluded that pooling of 5 samples is sufficient to detect the presence of SARS-CoV-2, especially when pooled in pre-RNA extraction phase (Alcoba-Florez et al., 2020; Volpato et al., 2020). However, this is in contrary to Yelin et. al. (2020) that positive samples can be detected in pool of up to 32 samples as this study shows that only five samples can be pooled efficiently. The prevalence rate of a certain area must also be considered as this contributes to the practicality and its cost-effectiveness (Dorfman, 1943) as a range of 3 to 10 pool sizes in a two-stage pooling algorithm can be used if there is a prevalence rate of 5% (Abdalhamid et al., 2020). Further, pooling of samples prior to RNA significantly portrays that a high number of diagnostic resources may be conserved compared when samples are pooled after RNA extraction as it causes delay of individual sample detection, as positive pools need to be deconvoluted and is also prone to degradation of protein level. There were only limited studies who conducted pooled testing on both pre- and post-RNA extraction phases (Chhikara et. al., 2020; Volpato et. al., 2020; Mulu et. al., 2020) thus, this study has added knowledge on this concept.

As shown in this study, only N gene was detected on all known individual positive samples when pooled in five in pre-RNA extraction phase. When validated and analyzed on unknown samples, it was found out that this gene is more sensitive and has higher positive predictive value and negative predictive value, however, RdRp is more specific. To the best of our knowledge, target gene performance was only evaluated on individual samples. According to Benrahma et. al. (2020), N gene is persistently detected in samples with Ct value of ≤ 40 in RT-PCR having similar viral detection kit used in this study. This may explain due to its abundant production within infected cells having multiple functions such as replication, transcription, translation and specifically binding to viral RNA to form the ribonucleocapsid (McBride, Van Zyl and Fielding,

2014). A comparative study of Vogels et. al. (2020) and Nalla et. al. (2020) also showed that N gene is found to be more sensitive than RdRp when tested on individual nasopharyngeal and oropharyngeal samples, and noticeably more when it is pooled as illustrated in this study. In addition, this is also emphasized when an evaluation of SARS-CoV-2 detection kit was done by Zhou et. al. (2020) and recommended by the study of Chu et. al. (2020) as a screening assay as N gene is ten times more sensitive than Orf1b in detecting positive samples. On the other hand, as RdRp is a viral enzyme with no host cell homolog that functions for viral RNA replication, this might explain why it has higher diagnostic performance (Zhu, et al., 2020).

The scope of this study is the diagnostic performance of the reagents and equipment used. Further, its limitation includes no analysis on the pooling of SARS-CoV-2 swabbed samples of the symptomatic and asymptomatic individuals as only de-identified samples were utilized. Overall, this study serves as a proof of concept of the pooling method, illustrating the results of the different pooling sizes on both RNA extraction phases, of SARS-CoV-2 using RT-PCR technique. In conclusion, this study found out that 5-pooled sample has better diagnostic performance compared to 10-pooled samples as, specifically, all positive individual samples were only detected in 5-pooled samples in pre-RNA extraction phase which these results are evident and consistent on both known and unknown samples. Further, N gene was found out to detect more SARS-CoV-2 samples compared to RdRp.

Based on the results of this study, the following are hereby recommended for future research and development work:

For research institutes:

- Given the scope of this study, a validation on pooling method using other diagnostic reagents and equipment must also be done as its performance may vary and may not be similar with the results shown in this study.
- To address the limitation of this study, consider symptom profile and its duration when pooling of SARS-CoV-2 swabbed samples.
- If incidence or surveillance of COVID-19 is aimed for the study, a pooled testing method is suggested to lessen the workload and resources used while at the same time having a reliable result compared to using rapid diagnostic kits. The results may also be a significant basis for policy- making in the respective areas.

For policymakers:

- Based on the results of the study, pooling of five samples prior to RNA extraction must be used as it could possibly detect much positive samples even for a high cycle threshold value or low viral load compared to pooling of 10 samples that has a higher chance of missing out possible positive samples. Moreover, this could be a potential tool to hasten the process of tracking and isolating possible COVID-19 individuals.
- For pooling of SARS-CoV-2, the following reagents and equipment are hereby suggested as these shows satisfactory performance: Genolution Nextractor® NX-48S for RNA extraction, GeneFinder™ COVID-19 Plus RealAmp Kit for SARS-CoV-2 viral detection and Applied Biosystems® 7500 Real-Time PCR Instrument (ABI 7500; Thermo Fisher Scientific Inc.) for PCR machine.

REFERENCES

1. Abdalhamid, B., Bilder, C.R., McCutchen, E.A., Hinrichs, S.H., Koepsell, S.A., & Iwen, P.C. (2020). Assessment of Specimen Pooling to Conserve SARSCoV-2 Testing Resources. *Am J Clin Pathol*, XX: 1-4. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188150> DOI: 10.1093/ajcp/aqaa064
2. Alcoba-Florez, J., Gil-Campesino, H., Garcia-Martinez de Artola, D., Valenzuela-Fernandez, A., Gonzales-Montelongo, R., Ciuffreda, L., Flores, C. (2020). Increasing SARS-CoV-2 RT-qPCR testing capacity by sample pooling. *Int J Infect Dis*, S1201-9712(20)32468-1. DOI: <https://doi.org/10.1016/j.ijid.2020.11.155>
3. Benrahma, H., Diawara, I., Smyej, I., Rahoui, J., Meskaoui, N., Benmessaoud, R., Arouro, K., Jaras, K., Adam, Z., Nahir, S., Aouzal, Z., Elguazzar, H., Jeddane, L., Ousti, F., Elbakkouri, J., Nejjari, C. (2020). Epidemiological description and analysis of RdRp, E and N gene dynamic by RT-PCR of SARS-CoV-2 in Moroccan population: Experience of the National Reference Laboratory (LNR)-UM6SS. *medRxiv*. DOI: <https://doi.org/10.1101/2020.06.18.20135137>
4. Bi, Q., Wu, Y., Mei, S., Ye, C., Zou X., Zhang, Z., Liu, X., Wei L., Truelove, S.A., Zhang, T., Gao, W., Cheng, C., Tang, X., Wu, X., Wu, Y., Sun, B., Huang, S., Sun, Y., Zhang, J., . . . Feng, T. (2020). Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis*, 20: 911-19. Retrieved from: [https://doi.org/10.1016/S1473-3099\(20\)30287-5](https://doi.org/10.1016/S1473-3099(20)30287-5)
5. Center for Disease Control and Prevention (2020, August 1). *Interim Guidance for Use of Pooling Procedures in SARS-CoV-2 Diagnostic, Screening, and Surveillance Testing*. Atlanta, Georgi: CDC. Retrieved from: <https://www.cdc.gov/coronavirus/2019-ncov/lab/pooling-procedures.html>
6. Chhikara, K., Kanta, P., Ghosh, A., Prakash, R.C., Goyal, K., Singh, M.P. (2020). Validation of SARS CoV-2 detection by real-time PCR in matched pooled and deconvoluted clinical samples before and after nucleic acid extraction: a study in tertiary care hospital of North India. *Diagn Microbiol Infect Dis*. 99(1):115206. DOI: 10.1016/j.diagmicrobio.2020.115206
7. Department of Health. (2020, September). COVID-19 Tracker. Manila, Philippines: DOH. Retrieved from: <https://ncovtracker.doh.gov.ph>
8. Department of Health. (2020, August) Philippines Now Has 100 Licensed Testing Labs-DOH. Manila, Philippines: DOH. Retrieved from: <https://www.doh.gov.ph/doh-press%20release/PHILIPPINES-NOW-HAS-100-LICENSED-TESTING-LABS-%E2%80%93-DOH>
9. de Salazar, A., Aguilera, A., Trastoy, R., Fuentes, A., Alados, J., Causse, M., & Galán, J., Moreno, A., Trigo, M., Perez, M., Roldan, C., Jose Pena, A., Bernal, S., Serrano-Conde, E., Barbeito, G., Torres, E., Riazzi, C., Cortes-Cuevas, J.L., Chueca, N., . . . Garcia, F. (2020). Sample Pooling for SARS-COV-2 RT-PCR screening. *Clinical Microbiology and Infection*. Retrieved from: <https://doi.org/10.1016/j.cmi.2020.09.008>
10. Dorfman, R. (1943). The Detection of Defective Members of Large Population. *The Annals of Mathematical Statistics*, 14(4): 436-440. Retrieved from: <https://projecteuclid.org/euclid.aoms/1177731363>

11. European Center for Disease Prevention and Control (2020, May 28). *Methodology for estimating point prevalence of SARS-CoV-2 infection by pooled RT-PCR testing*. Stockholm, Sweden: ECDC. Retrieved from: <https://www.ecdc.europa.eu/en/publications-data/methodology-estimating-point-prevalence-sars-cov-2-infection-pooled-rt-pcr>
12. Galvez, D. (2020, May 20). DOH: No shortage in COVID-19 test kits in the Philippines. *INQUIRER.net*. Retrieved from: <https://newsinfo.inquirer.net/1278019/doh-no-shortage-in-covid-19-test-kits-in-philippines#ixzz6ZFcJ0uHJ>
13. Gupta, E., Padhi, A., Khodare, A., Agarwal, R., Ramachandran, K., Mehta, V., Kilikdar, M., Dubey, S., Kumar, G., Sarin, S.K. (2020). Pooled RNA sample reverse transcriptase real time PCR assay for SARS CoV-2 infection: A reliable, faster and economical method. *PLoS ONE* 15(7): e0236859. DOI: <https://doi.org/10.1371/journal.pone.0236859>
14. Hogan C. A., Sahoo, M.K., Pinsky, B.A. (2020). Sample Pooling as a Strategy to Detect Community Transmission of SARS. *JAMA* 323(19):1967–1969. Retrieved from JAMA: <https://jamanetwork.com/journals/jama/article-abstract/2764364> DOI: doi:10.1001/jama.2020.5445
15. Lohse, S., Pfuhl, T., Berkó-Göttel, B., Rissland, J., Geißler, T., & Gärtner, B., Becker, S.L., Schneitler, S., Smola, S. (2020). Pooling of samples for testing for SARS-CoV-2 in asymptomatic people. *Lancet Infect Dis*. DOI: [https://dx.doi.org/10.1016%2FS1473-3099\(20\)30362-5](https://dx.doi.org/10.1016%2FS1473-3099(20)30362-5)
16. Majid F., Omer, S.B., Khwaja, A.I. (2020). Optimizing SARS-CoV-2 Pooled Testing for Low Resource Setting. *Lancet Microbe* 1(3): e101–e102. DOI: [https://dx.doi.org/10.1016%2FS2666-5247\(20\)30056-2](https://dx.doi.org/10.1016%2FS2666-5247(20)30056-2)
17. McBride, R., Van Zyl, M., Fielding, B.C. (2014). The Coronavirus Nucleocapsid Is a 333 Multifunctional Protein. *Viruses*, 6(8): pp. 2991-3018.
18. Mulu, A., Alemayehu, D., Alemu, F., Tefera, D., Wolde, S., Aseffa, G., Seyoum, T., Habtamu, M., Abdissa, A., Bayih, A.G., Beyene, G. (2020). Evaluation of Sample Pooling for Screening of SARS-CoV-2. *Research Square*. DOI: <https://doi.org/10.21203/rs.3.rs-30071/v1>
19. Nalla, A.K., Casto, A.M., Huang, M.W., Perchetti, G.A., Sampoleo, R., Shrestha, L., Wei, Y., Zhu, H., Jerome, K.R., Greninger, A.L. (2020). Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. *J Clin Micro* 58(6): e00557-20. DOI: 10.1128/JCM.00557-20
20. Owens-Liston, P. (2020). *When COVID-19 Testing Supply Shortages Hit, This Behind-the-Scenes Lab Improvised and Innovated Fast*. Salt Lake City: ARUP Laboratories News. Retrieved from: <https://www.aruplab.com/index.php/news/5-22-2020/COVID-19-Testing-Supply>
21. Perchetti, G., Sullivan, K.-W., Pepper, G., Huang, M.-L., Breit, N., Mathiasa, P., Jerome, K.R., Greninger, A. (2020). Pooling of SARS-CoV-2 samples to increase molecular testing throughput. *J Clin Virol* 131: 104570. DOI: <https://dx.doi.org/10.1016%2Fj.jcv.2020.104570>
22. Research Institute for Tropical Medicine. (2020, October) Viral Transport Media (VTM): RITM. Retrieved from: <http://ritm.gov.ph/data/covid-19-kit-evaluation/viral-transport-media-vtm/>
23. Scott K. (2020, April 10). *Supply Shortages Continue to Hamper COVID-19 Testing*. Clinical Lab Manager. Retrieved from:

- <https://www.clinicallabmanager.com/insight/supply-shortages-continue-to-hamper-covid-19-testing-22291>
24. Song, F. S., Shi, N., Shan, F., Zhang, Z., Shen, J., Lu, H., Ling, Y., Jiang, Y., Shi, Y. (2020). Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. *Radiology* 295(1):210-217. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/32027573/> DOI: 10.1148/radiol.2020200274
25. United States Centre for Disease Prevention and Control (2020, August 1). *Interim Guidance for Use of Pooling Procedures in SARS-CoV-2 Diagnostic, Screening, and Surveillance Testing*. Atlanta, USA: US CDC. Retrieved from: <https://www.cdc.gov/coronavirus/2019-ncov/lab/pooling-procedures.html>
26. Vogels, C.B.F., Brito, A.F., Wyllie, A.L., Fauver, J.R., Ott, I.M., Kalinich, C.C., Petrone, M.E., Casanovas-Massana, A., Muenker, M.C., Moore, A.J., Klein, J., Lu, P., Lu-Culligan, A., Jiang, X., Kim, D.J., Kudo, E., Mao, T., Moriyama, M., Oh, J.E., Grubaugh, N.D. (2020). Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets. *medRxiv*. Retrieved from: <https://doi.org/10.1101/2020.03.30.20048108>
27. Volpato, F., Lima-Morales, D., Wink, P.L., Willig, J., de-Paris, F., Ashton-Prolla, P., Barth, A.L. (2020) Pooling of samples to optimize SARS-CoV-2 diagnosis by RT-qPCR: comparative analysis of two protocols. *Eur J Clin Microbiol Infect Dis*, 1-4. DOI: 10.1007/s10096-020-04071-8.
28. World Health Organization (2020, August 6). *WHO Coronavirus (COVID-19) Dashboard*. Geneva, Switzerland: World Health Organization. Retrieved from: <https://covid19.who.int>
29. World Health Organization (2020, Jan 30). *Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)*. Geneva, Switzerland: World Health Organization. Retrieved from: [https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
30. Yelin, I., Aharoni, N., Tamar, E., Argoetti, A., Messer, E., Berenbaum, D., Shafran, E., Kuzli, A., Gandali, N., Shkedi, O., Hashimshony, T., Mandel-Gutfreund, Y., Halberthal, M., Geffen, Y., Szwarcwort-Cohen, M., Kishony, R. (2020). Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools. *Clin Infect Dis*, ciae531. DOI: 10.1093/cid/ciae531 Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/32358960/>
31. Zhou, Y., Pei, F., Ji, M., Zhao, H., Li, H., Yang, W., Wang, Q., Zhao, Q., Wang, Y. (2020). Sensitivity evaluation of 2019 novel coronavirus (SARS-CoV-2) RT-PCR detection kits and strategy to reduce false negative. *PLoS ONE*: 15(11): e0241469. <https://doi.org/10.1371/journal.pone.0241469>
32. Zhu, W., Chen, C.Z., Gorshkov, K., Xu, M., Lo, D.C., Zheng, W. (2020). RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. *SLAS DISCOVERY: Advancing the Science of Drug Discovery*: 25(10):1141-1151. DOI:10.1177/2472555220942123

APPENDICES

I. Pooling Procedure

Supplementary Figure S1. Illustration of 5-pooled samples with one positive sample (red circle) and four negative samples (white circle) in each of the Ct value ranges given and pooled in two phases: pre-RNA extraction and post RNA extraction. These were done in three replicates.

Supplementary Figure S2. Illustration of 10-pooled samples with one positive sample (red circle) and nine negative samples (white circle) in each of the Ct value ranges given and pooled in two phases: pre- RNA extraction and post RNA extraction. These were done in three replicates.

II. Raw data and statistical formula and analysis

Supplementary Table S1. Cycle threshold values of individual positive samples in 5-pooled pre-RNA extraction phase.

Positive Sample No.	Pool ID	Individual samples		5-pooled samples	
		N gene	RdRp	N gene	RdRp
1	A5	19.06	19.85	21.21	21.84
2		17.12	17.31	21.21	21.84
3	E5	37.33	40.8	22.34	22.16
4		19.5	19.51	22.34	22.16
5	G5	35.87	40.95	36.04	40.21
6	I5	25.51	25.75	23.68	23.61
7		25.29	26.57	23.68	23.61
8	J5	27.24	28.88	23.28	23.52
9	K5	32.84	35.8	37.14	39.01
10	P5	24.34	29.07	22.51	23.12
11	S5	33.39	36.15	31.88	32.78
12	T5	23.87	24.39	26.72	27.38
13		27.06	29.03	26.72	27.38
14	U5	27.42	24.35	26.06	25.32
15	V5	23.68	24.43	28.25	28.94
16	W5	30.22	30.49	24.23	23.92
17		21.01	20.58	24.23	23.92
18	X5	21.97	21.3	24.36	25.61
19	Y5	34.67	35.2	37.62	UND
20		35.82	34.76	37.62	UND
21		33	34.13	37.62	UND
22	Z5	28.97	29.66	31.69	32.45
23	B51	31.34	31.77	35.44	36.94
24	C51	37.11	UND	37.96	UND
25		35.91	40.61	37.96	UND
26	D51	31.1	32.4	33.2	33.72
27		32.44	32.73	33.2	33.72
28	G51	31.71	32.76	35.42	41.5
29	N51	33.73	34.01	36.05	37.61
30	X51	38.84	37.26	35.89	38.97
31	Y51	UND	37.65	37	38.7

UND: Viral gene is undetected

Supplementary Table S2. Comparison of mean Ct value of 5- and 10-pooled samples in pre-extraction phase with a Ct value of <24.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
5-pooled	15	19.14	0.87			
10-pooled	30	20.48	0.36			
Result	<i>t</i> statistics	<i>df</i>	p-value¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-7.33394	43	<0.0000001	-1.34	-1.70848	-0.971524
Unequal variance	-5.72524	16	0.00003129	-1.34	-1.83616	-0.843837
		<i>F</i> statistics	<i>df</i>(numerator,denominator)	p-value¹		
Test for equality of variance ²		5.84028	14,29	0.00006244		

¹ p-value (two-tailed)

Supplementary Table S3. Comparison of mean Ct value of 5- and 10-pooled samples in pre-extraction phase with a Ct value of 25-28.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
5-pooled	15	26.08	0.62			
10-pooled	30	27.16	1.15			
Result	<i>t</i> statistics	<i>df</i>	p-value¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-3.38648	43	0.001523	-1.08	-1.72316	-0.436842
Unequal variance	-4.0905	43	0.0001854	-1.08	-1.61246	-0.547537
		<i>F</i> statistics	<i>df</i>(numerator,denominator)	p-value¹		
Test for equality of variance ²		3.44043	29,14	0.01785		

¹ p-value (two-tailed)

Supplementary Table S4. Comparison of mean Ct value of 5- and 10-pooled samples in pre-extraction phase with a Ct value of 29-32.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
5-pooled	15	31.01	0.53			
10-pooled	30	32.76	1.8			
Result	<i>t</i> statistics	<i>df</i>	p-value¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-3.66773	43	0.0006695	-1.75	-2.71224	-0.787761
Unequal variance	-4.91591	38	0.00001726	-1.75	-2.47066	-1.02934
		<i>F</i> statistics	<i>df</i>(numerator,denominator)	p-value¹		
Test for equality of variance ²		11.5344	29,14	0.00001987		

¹ p-value (two-tailed)

Supplementary Table S5. Comparison of mean Ct value of 5- and 10-pooled samples in pre-extraction phase with a Ct value of 33-36.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
5-pooled	15	32.29	0.03			
10-pooled	30	35.02	1.21			
Result	<i>t</i> statistics	<i>df</i>	p-value¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-8.68657	43	<0.0000001	-2.73	-3.36381	-2.09619
Unequal variance	-12.3501	29	<0.0000001	-2.73	-3.1821	-2.2779
		<i>F</i> statistics	<i>df</i>(numerator,denominator)	p-value¹		
Test for equality of variance ²		1626.78	29,14	<0.0000001		

¹ p-value (two-tailed)

Supplementary Table S6. Comparison of mean Ct value of 5- and 10-pooled samples in post extraction phase with a Ct value of <24.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
5-pooled	15	21.51	0.71			
10-pooled	30	22.24	0.06			
Result	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-5.65648	43	0.000001153	-0.73	-0.990267	-0.469733
Unequal variance	-3.97499	14	0.001382	-0.73	-1.12388	-0.336115
		<i>F</i> statistics	<i>df</i> (numerator,denominator)		p-value ¹	
Test for equality of variance ²		140.028	14,29		<0.0000001	
¹ p-value (two-tailed)						

Supplementary Table S7. Comparison of mean Ct value of 5- and 10-pooled samples in post extraction phase with a Ct value of 25-28.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
5-pooled	15	28	0.06			
10-pooled	30	29.4	0.16			
Result	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-32.6047	43	<0.0000001	-1.4	-1.48659	-1.31341
Unequal variance	-42.3401	41	<0.0000001	-1.4	-1.46678	-1.33322
Test for equality of variance ²		<i>F</i> statistics	<i>df</i> (numerator,denominator)	p-value ¹		
		7.11111	29,14	0.0003708		
¹ p-value (two-tailed)						

Supplementary Table S8. Comparison of mean Ct value of 5- and 10-pooled samples in post extraction phase with a Ct value of 29-32.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
5-pooled	15	34.12	2.52			
10-pooled	30	33.38	0.88			
Result	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	1.4541	43	0.1532	0.74	-0.28631	1.76631
Unequal variance	1.10414	16	0.2859	0.74	-0.680758	2.16076
		<i>F</i> statistics	<i>df</i> (numerator,denominator)	p-value ¹		
Test for equality of variance ²		8.20041	14,29	0.000002174		
¹ p-value (two-tailed)						

Supplementary Table S9. Comparison of mean Ct value of 5- and 10-pooled samples in post extraction phase with a Ct value of 33-36.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
5-pooled	15	33.98	1.8			
10-pooled	30	34.62	0.45			
Result	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-1.85414	43	0.07059	-0.64	-1.33611	0.0561144
Unequal variance	-1.35604	15	0.1952	-0.64	-1.64596	0.365964
		<i>F</i> statistics	<i>df</i> (numerator,denominator)	p-value ¹		
Test for equality of variance ²		16	14,29	<0.0000001		
¹ p-value (two-tailed)						

Supplementary Table S10. Comparison of mean Ct value of pre- and post-RNA extraction phase in 5-pooled samples with a Ct value of <24.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
Pre-RNA Extraction	15	19.14	0.87			
Post-RNA Extraction	15	21.51	0.71			
<u>Result</u>	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-8.17403	28	<0.0000001	-2.37	-2.96392	-1.77608
Unequal variance	-8.17403	27	<0.0000001	-2.37	-2.96491	-1.77509
Test for equality of variance ²		<i>F</i> statistics	<i>df</i> (numerator,denominator)		p-value ¹	
		1.50149	14,14		0.4566	
¹ p-value (two-tailed)						

Supplementary Table S11. Comparison of mean Ct value of pre- and post-RNA extraction phase in 5-pooled samples with a Ct value of 25-28.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
Pre-RNA Extraction	15	26.08	0.62			
Post-RNA Extraction	15	28	0.06			
<u>Result</u>	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-11.938	28	<0.0000001	-1.92	-2.24945	-1.59055
Unequal variance	-11.938	14	<0.0000001	-1.92	-2.26495	-1.57505
Test for equality of variance ²		<i>F</i> statistics	<i>df</i> (numerator,denominator)		p-value ¹	
		106.778	14,14		<0.0000001	
¹ p-value (two-tailed)						

Supplementary Table S12. Comparison of mean Ct value of pre- and post-RNA extraction phase in 5-pooled samples with a Ct value of 29-32.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
Pre-RNA Extraction	15	31.01	0.53			
Post-RNA Extraction	15	34.12	2.52			
Result	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-4.67742	28	0.00006698	-3.11	-4.47198	-1.74802
Unequal variance	-4.67742	15	0.0002977	-3.11	-4.52719	-1.69281
Test for equality of variance ²		<i>F</i> statistics	<i>df</i> (numerator,denominator)		p-value ¹	
		22.6073	14,14		0.000000670	
¹ p-value (two-tailed)						

Supplementary Table S13. Comparison of mean Ct value of pre- and post-RNA extraction phase in 5-pooled samples with a Ct value of 33-36.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
Pre-RNA Extraction	15	32.29	0.03			
Post-RNA Extraction	15	33.98	1.8			
<u>Result</u>	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-3.6358	28	0.001105	-1.69	-2.64215	-0.73785
Unequal variance	-3.6358	14	0.002700	-1.69	-2.68694	-0.693059
Test for equality of variance ²		<i>F</i> statistics	<i>df</i> (numerator,denominator)		p-value ¹	
		3600	14,14		<0.0000001	
¹ p-value (two-tailed)						

Supplementary Table S14. Comparison of mean Ct value of pre- and post-RNA extraction phase in 5-pooled samples with a Ct value of 37-40.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.	Std. Error		
Pre-RNA Extraction	15	34.82	2.15			
Post-RNA Extraction	15	41.85	7.94			
<u>Result</u>	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-3.3099	28	0.002574	-7.03	-11.3807	-2.67931
Unequal variance	-3.3099	16	0.004426	-7.03	-11.5325	-2.52751
Test for equality of variance ²		<i>F</i> statistics	<i>df</i> (numerator,denominator)	p-value ¹		
		13.6384	14,14	0.00001648		
¹ p-value (two-tailed)						

Supplementary Table S15. Comparison of mean Ct value of pre- and post-RNA extraction phase in 10-pooled samples with a Ct value of <24.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
Pre-RNA Extraction	30	20.48	0.36			
Post-RNA Extraction	30	22.24	0.06			
Result	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-26.4132	58	<0.0000001	-1.76	-1.89338	-1.62662
Unequal variance	-26.4132	31	<0.0000001	-1.76	-1.8959	-1.6241
Test for equality of variance ²		<i>F</i> statistics	<i>df</i> (numerator,denominator)		p-value ¹	
		36	29,29		<0.0000001	
¹ p-value (two-tailed)						

Supplementary Table S16. Comparison of mean Ct value of pre- and post-RNA extraction phase in 10-pooled samples with a Ct value of 25-28.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
	Sample size	Mean	Std. Dev.			
Pre-RNA Extraction	30	27.16	1.15			
Post-RNA Extraction	30	29.4	0.16			
Result	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-10.5669	58	<0.0000001	-2.24	-2.66433	-1.81567
Unequal variance	-10.5669	30	<0.0000001	-2.24	-2.67292	-1.80708
		<i>F</i> statistics	<i>df</i> (numerator,denominator)	p-value ¹		
Test for equality of variance ²		51.6602	29,29	<0.0000001		

¹ p-value (two-tailed)

Supplementary Table S17. Comparison of mean Ct value of pre- and post-RNA extraction phase in 10-pooled samples with a Ct value of 29-32.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
Pre-RNA Extraction	30	32.76	1.8			
Post-RNA Extraction	30	33.38	0.88			
Result	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	-1.69489	58	0.09546	-0.62	-1.35224	0.112236
Unequal variance	-1.69489	42	0.09750	-0.62	-1.35823	0.118229
		<i>F</i> statistics	<i>df</i> (numerator,denominator)	p-value ¹		
Test for equality of variance ²		4.18388	29,29	0.0002375		

¹ p-value (two-tailed)

Supplementary Table S18. Comparison of mean Ct value of pre- and post-RNA extraction phase in 10-pooled samples with a Ct value of 33-36.

TWO-SAMPLE INDEPENDENT <i>t</i> TEST						
Two-sided confidence interval		95%				
	Sample size	Mean	Std. Dev.			
Pre-RNA Extraction	30	35.02	1.21			
Post-RNA Extraction	30	34.62	0.45			
Result	<i>t</i> statistics	<i>df</i>	p-value ¹	Mean Difference	Lower Limit	Upper Limit
Equal variance	1.69709	58	0.09504	0.4	-0.0717986	0.871799
Unequal variance	1.69709	37	0.09808	0.4	-0.0775647	0.877565
Test for equality of variance ²		<i>F</i> statistics	<i>df</i> (numerator,denominator)	p-value ¹		
		7.23012	29,29	0.000000829		

¹ p-value (two-tailed)

III. Schematic diagram

Figure 1. Pooling procedure of known samples. (1) The usual RT-PCR process flow where individual samples underwent RNA extraction prior to RT-PCR testing. This was set as the gold standard of the analysis for this stage. Once Ct values of the individual samples were determined, these were then assigned to represent each of the Ct value ranges given with one positive and four negative samples each pool. (2) Known samples underwent pooling method prior to RNA extraction (5- and 10-pooling) then RT-PCR testing. (3) Known samples underwent pooling method after RNA extraction (5- and 10-pooling) then RT-PCR testing.

Figure 2. Pooling procedure of unknown samples. This is a schematic diagram of the second stage of the pooled testing method where unknown (clinical) SARS-CoV-2 samples were used. Individual and pooled samples were tested simultaneously. (1) The usual process flow where individual samples underwent RNA extraction prior to RT-PCR testing. This was set as the gold standard for this stage. (2) Validation of the first stage using unknown (clinical samples) pooled prior to RNA extraction.